Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid vs Raloxifene in Postmenopausal Women with Low BMD
NCT00431444Phase 4Completed
- Sponsor
- Novartis
- Start
- Jan 2007
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of zoledronic acid in osteoporosis (2 arms), sponsored by Novartis. Primary endpoint: Urine N-telopeptide of Type 1 Collagen at 6 months. Started Jan 2007; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00431444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00431444.